CytoSorbents appoints Alexander D'Amico as CFO effective August 7, 2023

Cytosorbents Corp

Annual base salary of $425,000; eligible for cash bonus up to 45% of salary based on milestones.
Received signing bonus of $5,000 and equity awards including 70,000 ISOs, 45,000 RSUs, 215,000 performance ISOs.
Employment agreement initial term through Dec 31, 2025, auto-renewing annually thereafter.
D'Amico previously CFO of Trulieve Cannabis; oversaw finance during revenue growth from $250M to $1.2B.
Outgoing CFO Kathy Bloch retiring after decade of service; transition managed.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alexander D'Amico

Chief Financial Officer

CTSO · Cytosorbents Corp

Effective: 2023-08-07
Filed: July 19, 2023, 7:59 PM ET

Mr. D’Amico will serve as the Company’s Chief Financial Officer, effective as of August 7, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexander D'Amico was appointed as Chief Financial Officer at Cytosorbents Corp.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Mr. D’Amico will serve as the Company’s Chief Financial Officer, effective as of August 7, 2023.

View on SEC.gov

Cytosorbents Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-082414

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.